image
Healthcare - Biotechnology - NASDAQ - US
$ 2.365
13.1 %
$ 168 M
Market Cap
-1.29
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one VTYX stock under the worst case scenario is HIDDEN Compared to the current market price of 2.37 USD, Ventyx Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one VTYX stock under the base case scenario is HIDDEN Compared to the current market price of 2.37 USD, Ventyx Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one VTYX stock under the best case scenario is HIDDEN Compared to the current market price of 2.37 USD, Ventyx Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VTYX

image
$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.815 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-148 M OPERATING INCOME
28.63%
-135 M NET INCOME
29.97%
-131 M OPERATING CASH FLOW
21.41%
-15.5 M INVESTING CASH FLOW
-15.36%
122 M FINANCING CASH FLOW
128.98%
0 REVENUE
0.00%
-30.1 M OPERATING INCOME
7.16%
-27.4 M NET INCOME
6.51%
-25.7 M OPERATING CASH FLOW
-10.62%
26.4 M INVESTING CASH FLOW
340.18%
0 FINANCING CASH FLOW
100.00%
Balance Sheet Ventyx Biosciences, Inc.
image
Current Assets 230 M
Cash & Short-Term Investments 217 M
Receivables 0
Other Current Assets 12.3 M
Non-Current Assets 46.9 M
Long-Term Investments 35.6 M
PP&E 10.3 M
Other Non-Current Assets 1.03 M
78.58 %4.45 %12.88 %3.72 %Total Assets$276.6m
Current Liabilities 12.8 M
Accounts Payable 3.13 M
Short-Term Debt 1.05 M
Other Current Liabilities 8.59 M
Non-Current Liabilities 9.74 M
Long-Term Debt 9.74 M
Other Non-Current Liabilities 0
13.90 %4.67 %38.17 %43.26 %Total Liabilities$22.5m
EFFICIENCY
Earnings Waterfall Ventyx Biosciences, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 148 M
Operating Income -148 M
Other Expenses -13.3 M
Net Income -135 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)000(148m)(148m)13m(135m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-53.19% ROE
-53.19%
-48.86% ROA
-48.86%
-56.05% ROIC
-56.05%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Ventyx Biosciences, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)202020202021202120222022202320232024202420252025
Net Income -135 M
Depreciation & Amortization 1.35 M
Capital Expenditures -241 K
Stock-Based Compensation 22.9 M
Change in Working Capital -10.6 M
Others -17.4 M
Free Cash Flow -131 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Ventyx Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for VTYX of $18.8 , with forecasts ranging from a low of $6 to a high of $50 .
VTYX Lowest Price Target Wall Street Target
6 USD 153.70%
VTYX Average Price Target Wall Street Target
18.8 USD 694.93%
VTYX Highest Price Target Wall Street Target
50 USD 2014.16%
Price
Max Price Target
Min Price Target
Average Price Target
5050454540403535303025252020151510105500Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Ventyx Biosciences, Inc.
image
Sold
0-3 MONTHS
2.02 K USD 1
3-6 MONTHS
79.5 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
301 K USD 1
3-6 MONTHS
960 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Event: Jefferies Global Healthcare Conference, New York Fireside ChatDate: Thursday, June 5, 2025 Time: 12:50-1:20 PM ET A webcast of the event will be available in the Investors and News section of the Ventyx website at  www.ventyxbio.com. globenewswire.com - 3 weeks ago
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson's disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported first quarter financial results and highlighted recent pipeline and business progress. “Ventyx has established itself as the leader in discovery and development of NLRP3 inhibitors with two novel compounds, VTX3232 and VTX2735 progressing through Phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications - disease states thought to be driven by pathologic activation of the NLRP3 inflammasome,” said Raju Mohan, PhD, President and Chief Executive Officer. globenewswire.com - 1 month ago
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program -- AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB): Mo Lamkanfi, PhD, Luke O'Neill, PhD, Ted Dawson, MD, PhD, Martin Pomper, MD, PhD, Antonio Abbate, MD, PhD, Paul Cremer, MD and Don Frail, PhD. The new SAB members have made vital discoveries in understanding the role of the NLRP3 inflammasome in neuro- and systemic inflammation, and are at the forefront of clinical development in neurodegenerative and cardiometabolic diseases. globenewswire.com - 2 months ago
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 biomarker study in patients with early Parkinson's disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported fourth quarter and full year 2024 financial results and highlighted recent pipeline and business progress. “Heading into 2025, Ventyx has established itself as the leader in the field of NLRP3 inhibition having progressed two novel inhibitors, VTX3232 and VTX2735, into Phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications. globenewswire.com - 3 months ago
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025 Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn's disease will be presented during the 20th Congress of the European Crohn's and Colitis Organisation (ECCO) being held in Berlin, Germany from February 19-22, 2025. “The Phase 2 data for VTX958 in Crohn's disease represent an important milestone for TYK2 inhibition in inflammatory bowel disease,” said Raju Mohan, PhD, Founder and Chief Executive Officer. globenewswire.com - 3 months ago
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. globenewswire.com - 4 months ago
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 globenewswire.com - 5 months ago
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company. globenewswire.com - 6 months ago
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: globenewswire.com - 7 months ago
Ventyx Biosciences: Ready To Escape "The Crash Cycle" Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials, I see obvious potential for Ventyx to outperform the market. Despite past troubles, management actions are addressing issues, though risks include volatility and the risk that drugs will not go commercial. seekingalpha.com - 7 months ago
VTYX Stock Rises on Strategic Equity Investment Deal With SNY Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232. zacks.com - 8 months ago
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX. benzinga.com - 8 months ago
8. Profile Summary

Ventyx Biosciences, Inc. VTYX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 168 M
Dividend Yield 0.00%
Description Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Contact 662 Encinitas Boulevard, San Diego, CA, 92024 https://www.ventyxbio.com
IPO Date Oct. 21, 2021
Employees 81
Officers Mr. Roy M. Gonzales CPA, M.B.A. Senior Vice President of Finance and Principal Financial & Accounting Officer Dr. Mark S. Forman M.D., Ph.D. Chief Medical Officer Dr. Sheila K. Gujrathi M.D. Executive Chairperson Dr. John M. Nuss Ph.D. Chief Scientific Officer Ms. Kathy Ogilvie Ph.D. Senior Vice President of Translational & Nonclinical Research Dr. Raju S. Mohan Ph.D. Founder, Chief Executive Officer, President & Director Mr. Matthew Richard Moore Chief Operating Officer Ms. Snehal Naik Ph.D. Senior Vice President of Clinical Development Ms. Rosa Ferrao Senior Vice President of Regulatory Affairs